Biotech designed first-of-its-kind therapy for rare cancer; waits for patients
(inquirer.com)
Within the next couple of weeks, the first blood samples from patients will arrive at the loading dock of Adaptimmune, a biotechnology company headquartered on the northeastern edge of the Navy Yard.
Within the next couple of weeks, the first blood samples from patients will arrive at the loading dock of Adaptimmune, a biotechnology company headquartered on the northeastern edge of the Navy Yard.